Issue 100

Dr Ben Sessa

Awakn's Dr Ben Sessa on therapist training and psychedelic healthcare on the NHS

Psychiatrist Dr Ben Sessa, Head of Psychedelic Medicine at Awakn Life Sciences, specialises in addiction services and psychedelic-assisted therapy.

PSYCH spoke with Dr Sessa regarding Awakn’s business model, therapist training and the potential of psychedelic healthcare on the NHS.

‘At Awakn we have two things we do,’ explained Dr Sessa. ‘Research and Development and commercialisation…We have just received approval of a grant from the UK government to cover 66% of the costs of the Phase III trial, which is a fascinating development.’

READ MORE

PSILOCYBIN THERAPY FOR ANOREXIA NERVOSA

In the UK over 100,000 suffer with anorexia nervosa. In the absence of treatments, researchers are studying the efficacy of psilocybin therapy.

Read More

QUALIFYING PSYCHEDELIC RESEARCH

Dr James Rucker, a Senior Lecturer at King’s College London, outlines how to identify the integrity of scientific studies in psychedelic research.

Read More

BUSINESS AND INVESTMENT

European drug developer Octarine Bio raises €2M.

Silo Pharma uplists to the NASDAQ.

The potential for psychedelic medicines in psychiatry.

The rise of the unregulated psilocybin market.

Biomind enters Phase II trial with 5-MeO-DMT analogue.

The fall in psychedelic healthcare stocks.

Mindset licenses preclinical compounds to Cybin.

SCIENCE AND RESEARCH

NZ$50m research facility for psychedelic medicine opens in Auckland.

The science of microdosing psychedelic medicines.

Ketamine in the treatment of levodopa-induced dyskinesia.

The impact of microdosing on meditation.

The Psychedelics as Medicine Report positions organisations in front of regulators, researchers and investors.

With over 60,000 downloads, the industry-leading publication contains proprietary market data and insights to identify emerging opportunities.

Previous partners include COMPASS Pathways, Cybin and Filament Health.

To be included in the fourth edition and to discuss future events, please contact grace@psych.global

CONTACT FORM

REGULATION AND LEGISLATION

Criticism of Colorado’s measure to legalise psychedelic medicines.

Draft of UK Mental Health Bill 2022.

ARTICLES OF INTEREST

WHO reports on mental health at work.

Implications of financial interest in psychedelic research.

Medical experts recommend screening for depression.

Psychedelic medicines for substance use disorder.

Partner with us